InvestorsHub Logo
Followers 883
Posts 304355
Boards Moderated 5
Alias Born 06/09/2006

Re: None

Thursday, 03/23/2017 9:08:19 AM

Thursday, March 23, 2017 9:08:19 AM

Post# of 16903
$RGBP ChemDiv Inc., a fully integrated target-to-clinic contract research organization, which is conducting the compound optimization studies for Regen BioPharma, has reported that they have synthesized more than 30 analogues of our initial small molecules and will begin screening them for activity in the coming weeks. Additionally, purified protein that will be used in these studies has been manufactured and received by the Company. Now that this crucial first phase has been completed, the Company can move forward with ChemDiv on the actual optimization process, which involves introducing the synthesized compound analogues to the special NR2F6 protein molecule and cellular systems.

https://finance.yahoo.com/news/regen-biopharma-inc-provides-nr2f6-120000232.html

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.